Echo Therapeutics Questions Qualifications Of Platinum Group's Board Nominee

(RTTNews) - Echo Therapeutics Inc. (ECTE), a medical device company developing its Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system, announced that it has mailed a letter to stockholders, questioning the qualifications of the Platinum Group's nominee, Shepard Goldberg, for election to the Echo Board of Directors.

In the letter, Echo Therapeutics highlighted the stark contrast between Goldberg's experience and that of the Echo Board's highly qualified and very experienced nominee, Robert Doman.

The Platinum Group is a dissident stockholder group led by Platinum Management (NY) LLC that is pursuing a proxy contest to elect Shepard Goldberg to the Echo Board at Echo's 2014 Annual Meeting of Stockholders in opposition to the company's experienced director and Interim CEO, Robert Doman.

Echo is being advised in connection with the proxy contest by Morgan, Lewis & Bockius LLP and Alston & Bird LLP. Laurel Hill Advisory Group, LLC is serving as Echo's proxy solicitor.